Capricor Therapeutics Faces Class Action Over Alleged Misleading Statements on Deramiocel Clinical Data
Event summary
- Rosen Law Firm filed a class action lawsuit against Capricor Therapeutics on behalf of investors who purchased securities between December 17, 2025, and July 26, 2026.
- The lawsuit alleges Capricor misled investors about changes to the statistical analysis plan for its Deramiocel cell therapy without FDA approval.
- Plaintiffs claim the FDA had not agreed to these changes before Capricor resubmitted its Biologics License Application (BLA).
- The lawsuit asserts that these actions created a substantial risk to regulatory approval of Deramiocel for Duchenne muscular dystrophy.
The big picture
This lawsuit highlights the critical importance of transparency in clinical trial data and regulatory compliance for biotech firms. The case underscores broader industry challenges around maintaining investor confidence amid evolving FDA standards, particularly for novel therapies like cell-based treatments. Capricor's ability to navigate this legal and regulatory hurdle will be a key test of its operational resilience.
What we're watching
- Regulatory Risk
- How the FDA's stance on Capricor's Deramiocel BLA will impact its approval timeline and investor confidence.
- Litigation Impact
- Whether the class action lawsuit will lead to significant financial or reputational damage for Capricor.
- Clinical Strategy
- The pace at which Capricor can address regulatory concerns and restore trust in its clinical data analysis methods.
Related topics